TY - JOUR
T1 - New antiplatelet agents
T2 - Why they are needed
AU - Franchini, Massimo
AU - Mannucci, Pier Mannuccio
PY - 2009/12
Y1 - 2009/12
N2 - Despite recent advances in the treatment of acute coronary syndromes (ACS), including dual antiplatelet therapy with aspirin and a thienopyridine during the acute phase and for secondary prevention, this condition remains a leading cause of morbidity and mortality. The limitations of the currently available antiplatelet agents have triggered the development of newer drugs. In this review we summarize the mechanisms of actions and results of current clinical trials of novel antiplatelet agents. These include prasugrel, a thienopyridine prodrug which has a mechanism similar to that of clopidogrel but superior pharmacokinetic features; ticagrelor, a non-thienopyridine that binds reversibly to the platelet P2Y
12 receptor; cangrelor, an intravenously administered analog of ticagrelor; the thrombin receptor antagonist SCH 53048; and terutroban (S18886), a thromboxane A
2 receptor inhibitor.
AB - Despite recent advances in the treatment of acute coronary syndromes (ACS), including dual antiplatelet therapy with aspirin and a thienopyridine during the acute phase and for secondary prevention, this condition remains a leading cause of morbidity and mortality. The limitations of the currently available antiplatelet agents have triggered the development of newer drugs. In this review we summarize the mechanisms of actions and results of current clinical trials of novel antiplatelet agents. These include prasugrel, a thienopyridine prodrug which has a mechanism similar to that of clopidogrel but superior pharmacokinetic features; ticagrelor, a non-thienopyridine that binds reversibly to the platelet P2Y
12 receptor; cangrelor, an intravenously administered analog of ticagrelor; the thrombin receptor antagonist SCH 53048; and terutroban (S18886), a thromboxane A
2 receptor inhibitor.
KW - Antiplatelet agents
KW - Cangrelor
KW - Prasugrel
KW - SCH 530348
KW - Terutroban
KW - Ticagrelor
UR - http://www.scopus.com/inward/record.url?scp=70350568827&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350568827&partnerID=8YFLogxK
U2 - 10.1016/j.ejim.2009.09.005
DO - 10.1016/j.ejim.2009.09.005
M3 - Article
C2 - 19892299
AN - SCOPUS:70350568827
VL - 20
SP - 733
EP - 738
JO - European Journal of Internal Medicine
JF - European Journal of Internal Medicine
SN - 0953-6205
IS - 8
ER -